US11406654B2 - Use of mannuronic diacid composition in treatment of Parkinson's disease - Google Patents

Use of mannuronic diacid composition in treatment of Parkinson's disease Download PDF

Info

Publication number
US11406654B2
US11406654B2 US17/256,807 US201917256807A US11406654B2 US 11406654 B2 US11406654 B2 US 11406654B2 US 201917256807 A US201917256807 A US 201917256807A US 11406654 B2 US11406654 B2 US 11406654B2
Authority
US
United States
Prior art keywords
total weight
composition
mannuronic
diacids
diacid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
US17/256,807
Other languages
English (en)
Other versions
US20210260089A1 (en
Inventor
Meiyu Geng
Xianliang Xin
Xiaoguang Du
Zhenqing Zhang
Jian Ding
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Institute of Materia Medica of CAS
Shanghai Green Valley Pharmaceutical Co Ltd
Original Assignee
Shanghai Institute of Materia Medica of CAS
Shanghai Green Valley Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Institute of Materia Medica of CAS, Shanghai Green Valley Pharmaceutical Co Ltd filed Critical Shanghai Institute of Materia Medica of CAS
Assigned to SHANGHAI GREEN VALLEY PHARMACEUTICAL CO., LTD., SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES reassignment SHANGHAI GREEN VALLEY PHARMACEUTICAL CO., LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DING, JIAN, DU, Xiaoguang, GENG, MEIYU, XIN, XIANLIANG, ZHANG, Zhenqing
Publication of US20210260089A1 publication Critical patent/US20210260089A1/en
Assigned to GREEN VALLEY (SHANGHAI) PHARMACEUTICALS CO., LTD. reassignment GREEN VALLEY (SHANGHAI) PHARMACEUTICALS CO., LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SHANGHAI GREEN VALLEY PHARMACEUTICAL CO., LTD.
Application granted granted Critical
Publication of US11406654B2 publication Critical patent/US11406654B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Definitions

  • the present invention relates to the use of an optimal composition of mannuronic diacids obtained by a biological activity evaluation method in the treatment of Parkinson's disease.
  • Parkinson's disease is a common neurodegenerative disease occurring in the middle-aged and elderly people over 50-60 years old. The main lesions are located in the nigra and striatum pathways, leading to resting tremor, hypertonia and bradykinesia. Parkinson's disease is the fourth most common neurodegenerative disease among the elderly people, with 1% of people over 65 years old suffering from this disease and 0.4% of people over 40 years old suffering from this disease.
  • the drugs for clinical treatment of Parkinson's disease are mainly compound levodopa formulation, dopamine receptor agonist, monoamine oxidase inhibitor, anticholinergic formulation and amantadine, etc., but there are some disadvantages such as large side effects and decreased long-term application effects.
  • Mannuronic diacids have been paid extensive attention due to their potential medicinal values. Mannuronic diacids are usually prepared by multiple steps with alginic acid as a raw material.
  • the polysaccharide molecule of the raw material, alginic acid comprises an M segment formed of D-mannuronic acids linked by ⁇ -1,4-glucosidic bonds, a G segment formed of L-guluronic acids linked by ⁇ -1,4-glucosidic bonds, and an MG segment formed by hybridization of the two sacchorides.
  • the structural formulae of D-mannuronic acid and L-guluronic acid are shown in the following Formula (I):
  • the M segment and the G segment can be separated from the raw material, alginic acids.
  • a common method can be simply described below: alginic acid is preliminarily degraded to give mixed polysaccharides of polymannuronic acid and polyguluronic acid; then the mixed polysaccharides are subjected to acidic precipitation to remove the polyguluronic acid therein, and further refinement is conducted to obtain a homopolymannuronic acid with a purity of more than 90% (hereinafter also referred to as “M-segment intermediate”). See, e.g., the methods disclosed in Chinese Patent Application No. 98806637.8 and CN02823707.2.
  • a common preparation method of oligomeric mannuronic acid is as follows: the M-segment intermediate obtained above is subjected to further acidolysis by heating under an acidic condition to obtain a small fragment mannuronic acid polymer having a desired molecular weight range.
  • the degradation efficiency can be improved by an oxidative degradation method; meanwhile, the reducing end can be oxidized to a ring-opened saccharic diacid, see Chinese Patent Application No. 200580009396.5 (Patent literature 1) filed by Meiyu Geng, et al. and U.S. Pat. No. 8,835,403 B2 (Patent literature 2) for details.
  • Patent literatures 1 and 2 are hereinafter collectively referred to as prior documents, of which are incorporated herein by reference in their entirety.
  • reaction to obtain of mannuronic diacid disclosed in prior documents can be represented by the following reaction equation (II), that is, the aldehyde group at position C1 of mannuronic acid at the reducing end of oligomannuronic acid polysaccharide is oxidized to carboxyl group.
  • a commonly used oxidant is an alkaline copper sulfate solution, i.e. Fehling's reagent.
  • the reaction substrate polymannuronic acid i.e. the above M-segment intermediate
  • a copper sulfate solution is added to a copper sulfate solution and reacted in a boiling water bath for 15 minutes to 2 hours.
  • This method uses Cu 2+ ion as an oxidant to oxidize the aldehyde group, and a brick-red cuprous oxide precipitate is generated in the reaction. This reaction is often used to identify a reducing sugar.
  • oligomannaric acids have effects against Alzheimer's disease (AD) and Diabetes Mellitus.
  • the pathogenesis of Alzheimer's disease and type 2 diabetes is closely related to amyloids ( ⁇ -amyloid and amylin).
  • Amyloid protein aggregates and then produces protein oligomers, which further aggregate to form fibers.
  • These protein aggregates are cytotoxic, induces an oxidative reaction in cells to damage mitochondria, and triggers a cascade reaction such as inflammatory reaction, causing damages to a large number of neurons and ⁇ cells, and ultimately leading to onset of Alzheimer's disease and type 2 diabetes.
  • Oligomannaric acids target amyloid protein and antagonize the cascade reactions induced by the amyloid protein, and therefore have the effects of preventing and treating Alzheimer's disease and type 2 diabetes.
  • the prior document CN106344592A discloses the application of mannuronic acid oligosaccharide and its derivatives with carboxyl at position 1 of the reducing end in the treatment of Parkinson's disease, and also discloses the pharmacodynamic activity of tetrasaccharide-to-decasaccharide mixture in the treatment of Parkinson's disease.
  • the invention relates to the use of a mannuronic diacid oligosaccharide composition in the treatment of Parkinson's disease.
  • the present invention also relates to a method for treating Parkinson's disease, which comprises administering a therapeutically effective amount of the mannuronic diacid oligosaccharide composition of the present invention to a patient in need thereof.
  • the mannuronic diacid oligosaccharide composition disclosed by the present invention comprises mannuronic diacids having Formula (III) or a pharmaceutically acceptable salt thereof:
  • n is an integer selected from 1 to 9, in is selected from 0, 1 or 2, m′ is selected from 0 or 1, and
  • the mannuronic diacid composition having a specific consitution has a favorable effect on the treatment of Parkinson's disease, while reducing the production cost. Also, it is beneficial to improve the quality of life of patients due to the safety derived from natural products.
  • FIG. 1 shows mass spectra of disaccharide, trisaccharide and tetrasaccharide in product A.
  • FIG. 2 shows mass spectra of pentasaccharide, hexasaccharide and heptasaccharide in product A.
  • FIG. 3 shows mass spectra of octasaccharide, nonasaccharide and decasaccharide in product A.
  • FIG. 4 shows the effects of different oligosaccharide compositions and hexasaccharides on the crawling-down time of PD animals on the 11th day.
  • the samples corresponding to the numbers on the abscissa in the Figure are: i: control group; ii: model group; iii: product A; iv: product B; v: product C; vi: product D; vii: comparative experimental sample; viii: hexasaccharide.
  • FIG. 5 shows the effects of different oligosaccharide compositions and hexasaccharides on the latency of PD animals on the 11th day; wherein the symbols on the abscissa are the same as those in FIG. 4 .
  • FIG. 6 shows the effects of different oligosaccharide compositions and hexasaccharides on the crawling-down time of PD animals on the 14th day; wherein the symbols on the abscissa are the same as those in FIG. 4 .
  • FIG. 7 shows the effects of different oligosaccharide compositions and hexasaccharides on the latency of PD animals on the 14th day; wherein the symbols on the abscissa are the same as those in FIG. 4 .
  • FIG. 8 shows the effects of different oligosaccharide compositions and hexasaccharides on the crawling-down time of PD animals on the 17th day; wherein the symbols on the abscissa are the same as those in FIG. 4 .
  • FIG. 9 shows the effects of different oligosaccharide compositions and hexasaccharides on the latency of PD animals on the 17th day; wherein the symbols on the abscissa are the same as those in FIG. 4 .
  • the present invention relates to the use of the mannuronic diacid oligosaccharide composition in the treatment of Parkinson's disease.
  • the mannuronic diacid oligosaccharide composition used comprises mannuronic diacids having Formula (III) or a pharmaceutically acceptable salt thereof:
  • n is an integer selected from 1 to 9, in is selected from 0, 1 or 2, m′ is selected from 0 or 1, and
  • the mannuronic diacid oligosaccharide composition of the present invention is a mixture of mannuronic diacids with different polymerization degrees, and the main components thereof are mannuronic diacid oligosaccharides with a polymerization degree of 2 to 10.
  • the most active saccharides in mannuronic diacids are tetrasaccharide to decasaccharide, especially hexasaccharide.
  • the inventors have found that adding a certain proportion of less active disaccharide and trisaccharide to the most active tetrasaccharide to decasaccharide does not reduce the biological activity and even increases the activity under the same administration dosage in mass.
  • the product yield is also significantly higher than that disclosed in the prior applications.
  • the weight percentage content of mannuronic diacids with each of the polymerization degrees in the mannuronic diacid oligosaccharide composition is: disaccharide 5-25%, trisaccharide 15-30%, tetrasaccharide 15-28%, pentasaccharide 5-25%, hexasaccharide 2-20%, heptsaccharide 2-20%, octasaccharide 2-20%, nonasaccharide 2-20%, decasaccharide 2-20%.
  • the weight percentage content of oligosaccharides in the composition is: disaccharide 5-25%, trisaccharide 15-30%, tetrasaccharide 15-28%, pentasaccharide 10-20%, hexasaccharide 5-15%, heptsaccharide 3-10%, octasaccharide 2-5%, nonasaccharide 1-5%, decasaccharide 1-5%.
  • the weight percentage content of oligosaccharides in the composition is: disaccharide 10-20%, trisaccharide 18-30%, tetrasaccharide 15-28%, pentasaccharide 15-20%, hexasaccharide 5-10%, heptsaccharide 3-5%, octasaccharide 2-5%, nonaccharide 1-3%, decasaccharide 1-3%.
  • the pharmaceutically acceptable salt thereof can be sodium salt or potassium salt.
  • a high-activity oligosaccharide composition can be obtained, of which the activity is higher than that of the most active hexasaccharide.
  • the composition added with a specific proportion of disaccharide and trisaccharide has higher activity than the composition without disaccharide and trisaccharide.
  • the proportion of each oligosaccharide in the high-activity oligosaccharide composition can have the following proportion:
  • the medicament for the treatment of Parkinson'disease of the present invention comprises a mannuronic diacid oligosaccharide composition, which comprises mannuronic diacids having Formula (III) or pharmaceutically acceptable salts thereof, and one or more pharmaceutically acceptable carriers.
  • the medicament of the present invention can be in the form of tablets, hard capsules, soft capsules, enteric capsules, microcapsules, granules, syrups, injections, granules, emulsions, suspensions, solutions and sustained-release formulation for oral or non-oral administration.
  • the pharmaceutically acceptable carrier of the present invention refers to a pharmaceutically acceptable carrier known to those skilled in the art.
  • the pharmaceutically acceptable carrier of the present invention includes, but is not limited to, fillers, wetting agents, binders, disintegrants, lubricants, adhesive, glidants, taste masking agents, surfactants, preservatives, etc.
  • Fillers include, but are not limited to lactose, microcrystalline cellulose, starch, saccharide powder, dextrin, mannitol, calcium sulfate, etc.
  • Wetting agents and binders include, but are not limited to sodium carboxymethylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, gelatin, sucrose, polyvinylpyrrolidone, etc.
  • Disintegrants include, but are not limited to sodium carboxymethyl starch, crosslinked polyvinylpyrrolidone, crosslinked sodium carboxymethyl cellulose, low substituted hydroxypropyl cellulose, etc.
  • Lubricants include, but are not limited to, magnesium stearate, silica gel micropowder, talc, hydrogenated vegetable oil, polyethylene glycol, magnesium lauryl sulfate, etc.
  • Adhesive includes, but are not limited to, Arabic gum, alginic acid, calcium carboxymethylcellulose, sodium carboxymethylcellulose, glucose binders, dextrins, dextrose, ethyl cellulose, gelatin, liquid glucose, guar gum, hydroxyethylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, magnesium aluminum silicate, maltodextrin, methylcellulose, polymethacrylates, polyvinylpyrrolidone, pregelatinized starch, sodium alginate, sorbitol, starch, syrup, and tragacanth gum.
  • Glidants include, but are not limited to colloidal silica, powdered cellulose, magnesium trisilicate, silica and talc.
  • Taste masking agents include, but are not limited to, aspartame, stevioside, fructose, glucose, syrup, honey, xylitol, mannitol, lactose, sorbitol, maltitol, and glycyrrhizin.
  • Surfactants include, but are not limited to Tween-80 and poloxamer.
  • Preservatives include, but are not limited to, parabens, sodium benzoate, potassium sorbate, etc.
  • treatment generally refers to achieving a desired pharmacological and/or physiological effect. This effect can be preventive according to the complete or partial prevention of the disease or its symptoms; and/or can be therapeutic according to partial or complete stabilization or cure of the disease and/or side effects due to the disease.
  • treatment covers any treatment of a patient's disease, including: (a) prevention of diseases or symptoms occurring in patients who are susceptible to disease or symptoms but have not yet been diagnosed with the disease; (b) inhibiting the symptoms of the disease, i.e. preventing its development; or (c) relieving the symptoms of the disease, i.e. causing the disease or the deterioration of the symptoms.
  • the mannuronic diacid oligosaccharide composition for the treatment of Parkinson's disease of the present invention comprises mannuronic diacids having Formula (III) or a pharmaceutically acceptable salt thereof:
  • n is an integer selected from 1 to 9, in is selected from 0, 1 or 2, m′ is selected from 0 or 1, and
  • the preparation method of the mannuronic diacid oligosaccharide composition for the treatment of Parkinson's disease comprises the following steps:
  • the raw material M-segment intermediate used in the present invention can be prepared by a method known in the prior art, e.g., the methods disclosed in Chinese Patent Application No. 98806637.8 and CN02823707.2.
  • a common method can be simply described below: alginic acid is preliminarily degraded to give mixed polysaccharides of polymannuronic acid and polyguluronic acid; then the mixed polysaccharides are subjected to acidic precipitation to remove the polyguluronic acid therein, and further refinement is conducted to obtain a homopolymannuronic acid with a purity of more than 90%, i.e., an M-segment intermediate.
  • the M-segment intermediate is dissolved in an appropriate amount of water and stirred at room temperature or under heating condition. With continuous introduction of ozone, the reaction starts.
  • the pH value of the reaction can be adjusted to 3-13, preferably 4-10, more preferably 6-8 by dropwise adding dilute hydrochloric acid or dilute NaOH solution.
  • the temperature is preferably 0-70° C., more preferably 10-45° C.
  • the introduction of ozone is stopped and the pH is adjusted to neutral.
  • the reaction product obtained above is formulated into a solution at a concentration of about 10% and separated by a molecular cut-off membrane to remove degradation products below monosaccharide.
  • the retentate is collected.
  • the MWCO of the molecular cut-off membrane used is 1000 Da-3000 Da, preferably 2000 Da.
  • the collected liquid is concentrated on a rotary evaporator and dried under vacuum to obtain an oligomannuronic diacid mixture. After analysis, it is found that these products are all compositions of oligosaccharide from disaccharide to decasaccharide with contents being within certain proportion ranges. Specific examples of this preparation method can be found in examples 1-3, in which three compositions A, B and C were respectively prepared according to the aforementioned methods.
  • the oligosaccharide mixture obtained in step (1) is dissolved to a concentration of about 10%, separated on a P6 gel chromatographic column, and subjected to ultraviolet detection to collect each effluent component.
  • the components having the same polymerization degree are combined.
  • Nine components of disaccharide to decasaccharide were collected, desalted by G10 gel column chromatography, concentrated by rotary evaporator, and dried in vacuum.
  • a specific purification and preparation process is shown in example 4.
  • the operations such as column chromatography, desalting and drying are known to those skilled in the art.
  • the prepared composition is compared with the hexasaccharide purified in step (2) for the pharmacological activity.
  • the results show that the oligosaccharide composition of the present invention is significantly better than the most active hexasaccharide in the oligosaccharides with single polymerization degree, while the activity of the composition without disaccharide and trisaccharide is slightly lower than that of hexasaccharide. Accordingly, it can be seen that the oligosaccharides with different polymerization degrees can play a synergistic effect after being combined.
  • the proportion of disaccharide to hexasaccharide in the composition is no less than 60%, and the proportion of disaccharide and trisaccharide is less than 60%, the activity of the composition is the highest. However, when the proportion of disaccharide and trisaccharide is more than 60%, the activity of the composition would also decrease.
  • mice were randomly divided into 8 groups: blank control group, MPTP model group and dosing group, with 14 animals in each group. Animals were divided into groups and given drugs on the same day. The blank control group and the MPTP model group were given saline solution by intragastric administration, and the other groups were given corresponding drugs once a day for 17 consecutive days. Modeling drugs were given from the 6th day. The animals in the blank control group were given 10 ml/kg of saline subcutaneously, and the other animals were given 25 mg/kg of MPTP subcutaneously once a day for five days.
  • MPTP has selective destructive effect on dopaminergic neurons in substantia nigra.
  • MPTP-induced PD animal model is the most classical animal model similar to pathological changes and clinical characteristics of human Parkinson's disease.
  • the main symptoms of PD are resting tremor, increased muscle tension, decreased movement, etc.
  • the turning time and climbing-down time of rod climbing experiment can represent the overall activity and coordination ability of mice.
  • An M-segment intermediate was prepared by the method disclosed in prior patents. The specific operations are briefly described below: 5 kg of sodium alginate was formulated into a solution of about 10%, and the pH was adjusted to about 3.0 by adding dilute hydrochloric acid. The solution was heated to 80° C., and stirred. It was allowed to react for 10 hr before the heating was stopped. After cooling to room temperature, the pH was adjusted to 9.0 by adding NaOH, and further adjusted to 2.85 by adding dilute hydrochloric acid. The solution was centrifuged at 5000 rpm for 10 min. The supernatant was collected, and adjusted to pH 1.0 by adding HCl.
  • the precipitate was collected, concentrated on a rotary evaporator, and dried under vaccum to give 1500 g of the M-segment intermediate.
  • 500 g of the M-segment intermediate was weighed, and dissolved in distilled water to prepare a solution in a volume of 5 L.
  • the solution was adjusted to pH 6.5 with NaOH, and heated in a water bath to control the reaction temperature at 75° C.
  • the gas flow rate at the outlet of an oxygen cylinder and the power of an ozone generator were adjusted such that ozone was fed into the reaction solution at a mass concentration flow rate of 8 g/hr.
  • Step 2) Analysis of Proportions and structures of Oligosaccharides with Various Polymerization degrees in Mannuronic Diacid Product A
  • Step 3) LC-MS Analysis of Structures of Oligosaccharides with Various Polymerization Degrees in Mannuronic Diacid Product A
  • Mass spectrometry conditions Agilent 6540 QTOF; ion source: ESI collision voltage 120 V; negative ion mode.
  • the width of the acquired signal (m/z) was 100-1000.
  • FIGS. 1-3 The mass spectra of oligosaccharides with various polymerization degrees are shown in FIGS. 1-3 .
  • Various signal peaks in the mass spectra were assigned, confirming the molecular structure of all oligosaccharides in product A, i.e., the structure shown in General Formula (III). See Table 1 below for the signal assignments and the structures corresponding to the signals.
  • oligosaccharides components with various polymerization degrees in B were determined by Superdex peptide molecular exclusion chromatography (GE Co.) in combination with multi-angle laser light scattering (MALS, Wyatt Co.). The measurement method was the same as the relevant part in example 1. Test results: from disaccharide to decasaccharide were represented by dp2-dp10, respectively, dp2 was 20%, dp3 was 25%, dp4 was 19%, dp5 was 12%, dp6 was 9%, dp7 was 5%, dp8 was 5%, dp9 was 3% and dp10 was 2%.
  • oligosaccharides with various polymerization degrees in C were determined by Superdex peptide molecular exclusion chromatography (GE Co.) in combination with multi-angle laser light scattering (MALS, Wyatt Co.). The measurement method was the same as the relevant part in example 1. Test results: from disaccharide to decasaccharide were represented by dp2-dp10, respectively, dp2 was 8%, dp3 was 20%, dp4 was 28%, dp5 was 19%, dp6 was 13%, dp7 was 6%, dp8 was 3%, dp9 was 2%, and dp10 was 1%.
  • Sample preparation 300 g of mannuronic diacid product A prepared in example 1 was weighed, dissolved in water, prepared into 1000 mL of concentrated solution, and placed in a refrigerator at 4° C. for use. For each use, 50 mL was taken out and was 1:2 diluted with water, and then suction filtered through a 0.22 ⁇ m ultrafiltration membrane.
  • Chromatographic separation conditions The chromatograph was AKTA pure 150 (purchased from GE Co.) equipped with a UV detector and an automatic collector. Separation chromatographic column: 1.2 kg of BioGel P6 (purchased from Bio-Rad Co.) was mixed with deionized water, vacuum degassed, manually filled into a glass column (inner diameter: 10 cm), rinsed with 10 column volumes of pure water. The chromatographic column bed was stable and the height was 1.0 m. Then, the mobile phase was changed to a 0.02 M NaCl solution, and after equilibration with 10 column volumes, sample loading was initiated.
  • Sample loading and separation The flow rate of the pump was set at 1 mL/min. After 100 mL of the sample solution was pumped to the top of the column through the chromatograph's own pump, it was switched to the mobile phase and eluted at a flow rate of 5 mL/min. After outflow of the dead water volume, automatic collection was initiated and 50 mL was collected per tube.
  • a pharmacological activity evaluation was conducted between the compositions and hexasaccharide to examine the synergistic effect of the oligosaccharides with different polymerization degrees in the compositions and the range of proportions of the oligosaccharides.
  • Composition Product D is a composition of Composition Product D:
  • the mannuronic diacid oligosaccharides with single polymerization degree as prepared in example 4 were accurately weighed from disaccharide to decasaccharide by the polymerization degree.
  • the weight of each saccharide taken out was as follows: 3.0 g of disaccharide, 3.0 g of trisaccharide, 1.5 g of tetrasaccharide, 1.5 g of pentasaccharide, 0.4 g of hexasaccharide, 0.2 g of heptasaccharide, 0.2 g of octasaccharide, 0.1 g of nonasaccharide, and 0.1 g of decasaccharide. They were uniformly mixed to obtain 10 g of composition product D.
  • a tetrasaccharide-to-decasaccharide containing mixture was prepared by referring to the methods disclosed in examples 1 and 2 of the prior document CN106344592A.
  • 5 g of crude alginate oligosaccharide was prepared into a 5% (weight percentage) aqueous solution.
  • the fresh oxidant copper hydroxide was prepared by adding 25 ml of 5% (weight percent) copper sulfate solution to 50 ml of 10% (weight percent) sodium hydroxide solution and mixing immediately.
  • the fresh oxidant copper hydroxide was immediately added to 40 ml of the above 5% (weight percent) alginate oligosaccharide solution, while heated in a boiling water bath until no more brick red precipitates were produced.
  • the reaction system was centrifuged to remove the precipitate to obtain the supernatant. A little supernatant was added to the oxidant again to check whether there was still brick red precipitate produced.
  • the eluent as mobile phase was 0.2 mol L-1NH 4 HCO 3 .
  • Eluate from the column chromatography was sequentially collected by using a plurality of 5 ml test tubes, and then the saccharide content of the eluate in each test tube was detected by using a sulfuric acid-carbazole method. According to the detection results, eluates containing alginate oligosaccharide components with different molecular weights were respectively collected according to the detection results. According to the detection results, eluates containing alginate oligosaccharide components with different molecular weights were respectively concentrated under reduced pressure and lyophilized.
  • Alginate oligosaccharide mixture tetrasaccharide to decasaccharide mixture
  • oligosaccharide components with various polymerization degrees in comparative experimental samples was detected by using Superdex peptide (GE Co.) molecular exclusion chromatography combined with multi-angle laser scattering (MALS, Wyatt).
  • the determination method is the same as the relevant part in example 1.
  • Test results: tetrasaccharide to decasaccharide is represented by dp4-dp10, which is 10% dp4, 12% dp5, 13% dp6, 14% dp7, 15% dp8, 19% dp9 and 17% dp10, respectively.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
US17/256,807 2018-06-29 2019-06-28 Use of mannuronic diacid composition in treatment of Parkinson's disease Active US11406654B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810713411.3A CN110652516A (zh) 2018-06-29 2018-06-29 甘露糖醛二酸的组合物在治疗帕金森氏症中的应用
CN201810713411.3 2018-06-29
PCT/CN2019/093803 WO2020001640A1 (zh) 2018-06-29 2019-06-28 甘露糖醛二酸的组合物在治疗帕金森氏症中的应用

Publications (2)

Publication Number Publication Date
US20210260089A1 US20210260089A1 (en) 2021-08-26
US11406654B2 true US11406654B2 (en) 2022-08-09

Family

ID=68984646

Family Applications (1)

Application Number Title Priority Date Filing Date
US17/256,807 Active US11406654B2 (en) 2018-06-29 2019-06-28 Use of mannuronic diacid composition in treatment of Parkinson's disease

Country Status (7)

Country Link
US (1) US11406654B2 (https=)
EP (1) EP3815691A4 (https=)
JP (1) JP2021528460A (https=)
KR (1) KR20210038874A (https=)
CN (1) CN110652516A (https=)
AU (1) AU2019296851A1 (https=)
WO (1) WO2020001640A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114796243B (zh) * 2021-01-27 2024-04-05 中国海洋大学 一种甘露糖醛酸和益母草碱的药物组合物及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1736160A1 (en) 2004-03-24 2006-12-27 Ocean University of China Algin oligosaccharides and the derivatives thereof as well as the manufacture and the use of the same
CN101301310A (zh) 2007-05-08 2008-11-12 首都医科大学 褐藻多糖硫酸酯在预防和治疗帕金森病中的用途
CN103405468A (zh) 2013-08-16 2013-11-27 中国海洋大学 一种低分子量甘露糖醛酸寡糖在制备预防或治疗帕金森症的药物或保健品中的应用
CN103948611A (zh) 2014-03-31 2014-07-30 青岛海洋生物医药研究院股份有限公司 低聚古罗糖醛酸盐在制备防治帕金森症药物或制品中的应用
CN106344592A (zh) 2015-07-17 2017-01-25 上海绿谷制药有限公司 还原端1位为羧基的甘露糖醛酸寡糖及其衍生物在治疗帕金森氏症中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140371283A1 (en) * 2013-02-12 2014-12-18 Buck Institute For Research On Aging Hydantoins that modulate bace-mediated app processing
CN103800348B (zh) * 2014-03-13 2015-07-01 中国科学院海洋研究所 甘露葡萄糖醛酸寡糖在制备治疗或预防帕金森病和/或老年痴呆药物和/或保健品中的应用
JP6977059B2 (ja) * 2016-12-30 2021-12-08 シャンハイ、グリーン、バレー、ファーマスーティカル、カンパニー、リミテッドShanghai Green Valley Pharmaceutical Co., Ltd. マンヌロン二酸の組成物

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1736160A1 (en) 2004-03-24 2006-12-27 Ocean University of China Algin oligosaccharides and the derivatives thereof as well as the manufacture and the use of the same
US8835403B2 (en) * 2004-03-24 2014-09-16 Meiyu Geng Algin oligosaccharides and the derivatives thereof as well as the manufacture and the use of the same
CN101301310A (zh) 2007-05-08 2008-11-12 首都医科大学 褐藻多糖硫酸酯在预防和治疗帕金森病中的用途
CN103405468A (zh) 2013-08-16 2013-11-27 中国海洋大学 一种低分子量甘露糖醛酸寡糖在制备预防或治疗帕金森症的药物或保健品中的应用
CN103948611A (zh) 2014-03-31 2014-07-30 青岛海洋生物医药研究院股份有限公司 低聚古罗糖醛酸盐在制备防治帕金森症药物或制品中的应用
CN106344592A (zh) 2015-07-17 2017-01-25 上海绿谷制药有限公司 还原端1位为羧基的甘露糖醛酸寡糖及其衍生物在治疗帕金森氏症中的应用

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Azm, S. et al., American Journal of Alzheiner's Disease & Other Dementias, Effects of M2000 (D-Mannuronic Acid) on Learning, Memory Retrieval, and Associated Determinants in a Rat Model of Alzheimer's Disease, 2017, vol. 32, No. 1, pp. 12-21 (Year: 2017). *
Gustot, A. et al., Biochem. J., "Amyloid fibrils are the molecular trigger of inflammation in Parkinson's diseae", 2015, vol. 471, pp. 323-333 (Year: 2015). *
International Search Report and Written Opinion for Application No. PCT/CN2019/093803, dated Oct. 8, 2019, 16 pages.
Jiang, R.-w. et al., Acta Pharmacologica Sinica, "Synthesis and bioassay of beta-(1,4)-D-mannans as potential agents against Alzheimer's disease", 2013, vol. 34, pp. 1585-1591 (Year: 2013). *
Yang, Z. et al., Carbohydrate Polymers, "Preparation and characterization of oligomannuronates from alginate degraded by hydrogen peroxide", 2004, vol. 58, pp. 115-121 (Year: 2004). *

Also Published As

Publication number Publication date
WO2020001640A1 (zh) 2020-01-02
US20210260089A1 (en) 2021-08-26
AU2019296851A8 (en) 2021-07-01
EP3815691A4 (en) 2022-04-27
KR20210038874A (ko) 2021-04-08
JP2021528460A (ja) 2021-10-21
EP3815691A1 (en) 2021-05-05
AU2019296851A1 (en) 2021-01-28
CN110652516A (zh) 2020-01-07

Similar Documents

Publication Publication Date Title
US20220356202A1 (en) Composition of mannuronic diacid
US11406659B2 (en) Use of mannuronic diacid composition in treatment of inflammation
US11406654B2 (en) Use of mannuronic diacid composition in treatment of Parkinson's disease
US11406652B2 (en) Use of mannuronic diacid composition in treatment of diabetes
US11406651B2 (en) Use of mannuronic diacid composition in treatment of vascular dementia
US11406653B2 (en) Use of mannuronic diacid composition in treatment of pain
HK40014917A (en) Use of a composition of oligomeric mannuronic diacid for treating parkinson's disease
HK40016250A (en) Use of a composition of mannuronic diacids in the treatment of diabetes
US20220362271A1 (en) Use of mannuronic acid oligosaccharides or composition comprising same in treatment of th1-dominance related diseases
HK40016251A (en) Use of a composition of mannuronic diacids in the treatment of pain

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

AS Assignment

Owner name: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES, CHINA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GENG, MEIYU;XIN, XIANLIANG;DU, XIAOGUANG;AND OTHERS;REEL/FRAME:054779/0163

Effective date: 20201228

Owner name: SHANGHAI GREEN VALLEY PHARMACEUTICAL CO., LTD., CHINA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GENG, MEIYU;XIN, XIANLIANG;DU, XIAOGUANG;AND OTHERS;REEL/FRAME:054779/0163

Effective date: 20201228

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

AS Assignment

Owner name: GREEN VALLEY (SHANGHAI) PHARMACEUTICALS CO., LTD., CHINA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SHANGHAI GREEN VALLEY PHARMACEUTICAL CO., LTD.;REEL/FRAME:057567/0376

Effective date: 20210913

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STCF Information on status: patent grant

Free format text: PATENTED CASE

FEPP Fee payment procedure

Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY